The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Gray William Garrett since 2020.
This trader's CIK number is 1692961.
At the time of last reporting, Gray William Garrett was the Chief Financial Officer of Checkpoint Therapeutics, Inc.. (stock ticker symbol CKPT).
Also see all insider trading activities at Checkpoint Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | CKPT | 0 | $0 | 86,432 | $321,887 | 0 | $0 |
| 2024 | CKPT | 0 | $0 | 287,620 | $1,115,506 | 0 | $0 |
| 2023 | CKPT | 0 | $0 | 10,517 | $54,520 | 0 | $0 |
| 2022 | CKPT | 0 | $0 | 75,260 | $165,260 | 0 | $0 |
| 2021 | CKPT | 0 | $0 | 26,320 | $96,331 | 0 | $0 |
| 2020 | CKPT | 0 | $0 | 19,510 | $40,834 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-01 | CKPT | Sale | 12,322 | 4.05 | 49,904 |
| 2025-02-06 | CKPT | Sale | 74,110 | 3.67 | 271,983 |
| 2024-12-18 | CKPT | Sale | 268,432 | 4.01 | 1,076,412 |
| 2024-06-26 | CKPT | Sale | 13,038 | 2.06 | 26,858 |
| 2024-02-28 | CKPT | Sale | 2,035 | 2.07 | 4,212 |
| 2024-02-01 | CKPT | Sale | 4,115 | 1.95 | 8,024 |
| 2023-02-27 | CKPT | Sale | 1,914 | 4.66 | 8,919 |
| 2023-03-02 | CKPT | Sale | 3,591 | 5.00 | 17,955 |
| 2023-02-01 | CKPT | Sale | 3,154 | 4.79 | 15,107 |
| 2023-01-10 | CKPT | Sale | 1,858 | 6.75 | 12,539 |
| 2022-03-10 | CKPT | Sale | 38,197 | 1.89 | 72,306 |
| 2022-02-01 | CKPT | Sale | 37,063 | 2.51 | 92,954 |
| 2021-02-04 | CKPT | Sale | 26,320 | 3.66 | 96,331 |
| 2020-12-22 | CKPT | Sale | 2,406 | 2.79 | 6,712 |
| 2020-05-21 | CKPT | Sale | 17,104 | 2.00 | 34,122 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Gray William Garrett (Chief Financial Officer of Checkpoint Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.